linjc16/ctgov huggingface dataset:
Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes

Study Overview
=================
Brief Summary
-----------------
Heat Intolerance (HI) is a life threatening deficiency that can lead to heat exhaustion, heat stroke (and possibly death) in a large number of military and civilian occupational groups. We have demonstrated malfunction of transcriptional pathways in the heat stressed HI phenotype and an altered gene expression profile compared to Heat Tolerant (HT) individuals. Such differences are evident even under normothermic basal/comfort conditions. Heat and exercise challenges during the heat tolerance test (HTT) further emphasize the differences between the groups, particularly during recovery at comfort temperatures. Our results indicate that it may be possible to identify markers of heat intolerance. To achieve this goal, we plan to design a cellular (lymphocyte) HTT experimental model and detect gene expression profiles using customized DNA microarrays and bioinformatic tools (the genes selected will be based on our previous DNA microarray studies). Lymphocyte samples collected from HT and HI individuals under resting/comfort conditions will be examined. Treatments and analyses are designed to reveal HI-associated gene-expression profiles (constitutive or inducible), and thereby find lymphocyte markers to identify individuals predisposed to heat injury. The identification of such subjects could prevent unnecessary loss of life. Notably, the rapidly changing climate in our era increases the number of occupation/age groups in which manifestations of HI will appear.

Official Title
-----------------
Following Study: Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes

Conditions
-----------------
Heat Intolerance, Genotypic Variations, Gene Expression, Genomic Markers for Predisposition of Heat Intolerance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Experienced heat exhaustion or heat stroke in their past Participating in heat tolerance tests (HTT) Exclusion Criteria: Unambiguous result of the HTT HTT stop by the subject decision

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HI<br>Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance . | |
| HT<br>Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance . | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Impact of the Social Factors and Rehabilitation Program to Address the Implications on Kidney Failure in Hail

Study Overview
=================
Brief Summary
-----------------
The aims of our study to evaluate the effect of social factors and medical rehabilitation program on kidney function and quality of life among chronic kidney disease patients.

Detailed Description
-----------------
This study aims to evaluate the effect of social factors and medical rehabilitation program on kidney function and quality of life among chronic kidney disease patients. Identify the health problems facing patients with kidney failure in Hail region. Detect the reality of the problems facing patients with kidney failure in Hail region and ways to reduce them. Identify the family, psychological, economic and social problems facing patients with kidney failure in Hail region.

Official Title
-----------------
The Impact of the Social Factors and Medical Rehabilitation Program to Address the Implications on Kidney Failure Disease in Hail Region (Under the Vision 2030)

Conditions
-----------------
Chronic Renal Disease

Intervention / Treatment
-----------------
* Other: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participants with CKD stages (3 and 4) will be participated in this study, their ages ranged from 40 to 60 years. Both sexes will be included. Participants should be: Saudi persons living in Hail City, married, both genders, Exclusion Criteria: (1) Severe chronic cardiac problems. (2) Chronic chest disease. (3) Chronic inflammatory orthopedic disorders and rheumatoid arthritis. (4) Mental impairments.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control<br>patients will take medical treatment only patients will receive medical treatment in addition to aerobic exercises | Other: exercise<br>* aerobic and resisted ex<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-minute walk test (6MWT). And Kidney Disease and Quality of Life (KDQOL™-36) | 6-minute walk test (6MWT). And Kidney Disease and Quality of Life (KDQOL™-36) | after 6 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle power of lower limb | functional muscle test | after 6 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal failure patients -Saudi community - social program
The Impact of Continuous Transcutaneous CO2 (TCCO2) Monitoring in Extremely Low Birth Weight (ELBW) Infants

Study Overview
=================
Brief Summary
-----------------
An observational study comparing outcomes of Extremely Low Birth Weight (ELBW) infants that were monitored with non-invasive Transcutaneous CO2 (TCCO2) monitor to infants that were not monitored by TCCO2 monitor.

Official Title
-----------------
The Impact of Continuous Transcutaneous CO2 Monitoring (TCCO2) in Extremely Low Birth Weight (ELBW) Infants: A Prospective Observational, Multi-Center Study

Conditions
-----------------
ELBW - Extremely Low Birth Weight Infant, IVH- Intraventricular Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ELBW infants Need of respiratory support Exclusion Criteria: Parental refusal IVH before study entry chromosomal abnormalities congenital central nervous system (CNS) abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 0 Minutes
Maximum Age: 24 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>TCCO2 monitoring | |
| Control group<br>Routine monitoring | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IVH-Intraventricular Hemorrhage | Intraventricular Hemorrhage | Repeated scans until infant reaches corrected age of 42 weeks | 
| PVL- Periventricular Leukomalacia | Periventricular Leukomalacia | Repeated scans until infant reaches corrected age of 42 weeks |
Genetic Variants and Phenotypic Characteristics of Patients With T2DM

Study Overview
=================
Brief Summary
-----------------
Background: Genetic risk-markers associated with T2DM are thoroughly studied. So far, only a few genetic variants, also termed single nucleotide polymorphisms (SNP's), have been replicated in several studies and each of them gives only limited explanation for the growing incidence of T2DM. The hypothesis of the present study is that determination of combinations of genetic variants by SNP-chip technology may improve the prediction of T2DM, complications and efficacy of treatment compared to the methods previously used including genome wide association (GWA) studies. The SNP-chip/ DNA microarray makes it possible to study several SNP's association with T2DM, one by one but also in combination. Aims: To study whether specific genetic variants, and combinations of these, 1) are present with higher prevalence in patients with T2DM than in the normal population, 2) are associated with specific diabetes-related complications and 3) the effect of the anti-diabetic treatment. Methods: During the next three years 1000 patients with T2DM and 1000 healthy, non-diabetic persons will be included in the study, and examined by blood samples, a questionnaire and clinical evaluation, all in one visit. Initially, we will perform DNA analyses on blood samples from 372 patients included in another clinical study from our department. Description of genetics will be done by a DNA-chip with approximately 70 SNP's, which have previously been reported to be associated with T2DM. Results and conclusions: It is expected that the result of this project can help us predicting T2DM, diabetes-related complications and individualizing treatment to the individual patient with T2DM.

Official Title
-----------------
Genetic Variants and Phenotypic Characteristics of Patients With T2DM

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes Mellitus > 18 years and

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Type 2 Diabetic Patients | |
| 2<br>Non-diabetic individuals | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 Diabetes Mellitus, Genetic Variants, SNP, DNA microarray
ReCap Total Hip Resurfacing Prospective Data Collection

Study Overview
=================
Brief Summary
-----------------
Prospective data collection on survivorship of ReCap Total Hip Resurfacing

Detailed Description
-----------------
Detailed protocol not available

Official Title
-----------------
ReCap Total Hip Resurfacing Prospective Data Collection

Conditions
-----------------
Arthritis

Intervention / Treatment
-----------------
* Device: ReCap Total Hip Resurfacing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of hip joint arthritis Exclusion criteria: - less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hip Resurfacing<br> | Device: ReCap Total Hip Resurfacing<br>* ReCap Total Hip Resurfacing<br>* Other names: RECAP;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival rate |  | 10 yr |
A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether L5, one of the Low Density Lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.

Detailed Description
-----------------
Cardiovascular disease (CVD) is the most important cause of death of chronic kidney disease (CKD) and hemodialysis (HD) patients. Low Density Lipoprotein (LDL) is an essential indicator of CVD.The higher the plasma LDL level, the higher the risk of CVD. LDL is a heterogenous substance composed of different mass and size. Oxidized LDL (oxLDL) is the oxidation product of LDL and is the most important component of LDL associated with CVD. The oxLDL is mostly trapped within tissue and not easily to be detected from blood. L5 iw a kind of electronegative LDL and is associated with CVD in smokers and diabetic patients, even if these patients have normal plasma LDL. Uremia patients have lipid profile different from that of general people,while HD Patients have lower LDL and CKD patients have LDL higher than that of general population. Thus LDL plasma level cannot fully explain the high risk of CVD in CKD and HD patients. As patients with normal LDL but high L5 are prone to have CVD, we suspect there might be association of L5 with CVD in both CKD and HD patients.

Official Title
-----------------
L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients

Conditions
-----------------
Cardiovascular Disease, Chronic Kidney Disease Patients, Hemodialytic Patients, High LDL Level, High L5 Level

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of CKD clinical diagnosis of HD Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal<br>Healthy population | |
| CKD Patients<br>Chronic Kidney Disease, in Stage III-V | |
| HD patients<br>End-stage renal disease patients undergoing hemodialysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
L5, LDL, Cardiovascular disease, Chronic kidney disease, Hemodialysis
Effect of Dabigatran on Coagulation parameters-an ex Vivo Study

Study Overview
=================
Brief Summary
-----------------
Dabigatran represent a new class of promising anticoagulation agents. As an oral direct thrombin inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo effects of Pradaxa® on different coagulation parameters.

Detailed Description
-----------------
This mono-centric, open-label study is undertaken to validate the effects of Dabigatran on coagulation parameters in plasma samples of 70 patients after hip or knee replacement surgery treated with Dabigatran 150-220 mg/d. Plasma samples are obtained by blood collection before, after 2 hours and after 12-14 hours after Dabigatran dosing in steady state (on 3rd - 5th day).

Official Title
-----------------
Effect of Dabigatran on Coagulation Parameters in Patients Undergoing Elective Orthopaedic Surgery

Conditions
-----------------
Effect of Dabigatran in Laboratory Coagulation Parameters

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 y Exclusion Criteria: Hemorrhagic disorder Liver disease Anemia Severe renal impairment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
direct thrombin inhibitors, Dabigatran, Coagulation parameters
Trial of YUMI Uterine Manipulator

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the feasibility and safety of using a new device called Yukio's Uterine Manipulating Instrument (YUMI). The YUMI is a type of uterine manipulator. It is a reusable metal device designed to be simple and study. It is also adjustable in size which makes it easy for surgeons to use. It will be placed at the beginning of the surgery and removed at the end. This study will allow the researchers to find out if the surgeons find the YUMI effective and easy to use. It will also allow the researchers to see if the device is safe. This is the first time that the YUMI is being used in humans.

Official Title
-----------------
Pilot Trial of YUMI Uterine Manipulator

Conditions
-----------------
Gynecologic Condition, Scheduled for a Total Laparoscopic or Robotic-assisted Hysterectomy

Intervention / Treatment
-----------------
* Procedure: YUMI manipulator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant must be scheduled for a total laparoscopic or robotic-assisted hysterectomy for a gynecologic condition Participants must be 18 years of age or older Exclusion Criteria: Participant is not eligible if the surgeon does not plan to use a uterine manipulator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: total laparoscopic or robotic-assisted hysterectomy<br>The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form. | Procedure: YUMI manipulator<br> <br> * Other names: Yukio's Uterine Manipulating Instrument;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of successfully placed Uterine Manipulator | The YUMI manipulator will be considered successfully placed when the device is inserted into the uterus and secured in place to hold for the duration of the procedure. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Uterine Manipulator, Yukio's Uterine Manipulating Instrument (YUMI), 16-1397
Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG

Study Overview
=================
Brief Summary
-----------------
To determine if there is a difference between wireless ECG and wired ECG findings.

Detailed Description
-----------------
The aim of the study is to compare ECG recordings from the Signalife Fidelity 100 Wireless 12-lead ECG Monitor System to that of the GE 5000 Wired 12-lead ECG Monitor System during rest and while walking. We hypothesize that ECG recordings from the wireless system will be equivalent to recordings from the standard wired system.

Official Title
-----------------
Comparison of a Novel 12-Lead Wireless ECG and a Standard Wired ECG

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Recom Model 100
* Device: GE 5000 ECG Monitor System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy individuals, AND Age 18-64 Exclusion Criteria: Pregnant women, Prisoners, Have known cardiovascular disease, OR Do not pass the PAR-Q and/or show baseline ECG abnormalities.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy subjects<br>five male, five female, ages 18-64 | Device: Recom Model 100<br>* Battery Operated, Ambulatory, Digital Wireless ECG Monitor System<br>Device: GE 5000 ECG Monitor System<br>* Wired ECG system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG recordings from the wireless system will be equivalent to recordings from the standard wired system. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ECG, EKG, healthy subjects, electrocardiography, ambulatory
Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Study Overview
=================
Brief Summary
-----------------
Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.

Official Title
-----------------
Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Conditions
-----------------
Recurrent Urinary Tract Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women above 18 years old. premenopausal recurrent UTI Exclusion Criteria: pregnancy immunocompromised active malignancy HIV carrier

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MBL, UTI